United States

United States

While ICAP is renowned for its work supporting health in countries around the world, it also carries out vital initiatives in New York City that serve key communities and inform new approaches to global health.

From its headquarters at the Mailman School of Public Health, which is part of the Columbia University Irving Medical Center, ICAP draws on world-class resources and expertise to conduct research and design programs that transforms the health of people worldwide.

ICAP’s two research centers in New York City, the Bronx Prevention Center and the Harlem Prevention Center, carry out cutting-edge biomedical and public health investigations in areas that have been historically underserved and disproportionately impacted by HIV and, more recently, COVID-19 and mpox. ICAP works with local community-based organizations, religious leaders, and advocates to promote community awareness of and engagement with the research studies.

Through Columbia University, ICAP also supports additional COVID-19 surveys and various student fellowship programs, engaging students to participate in the design, implementation, and evaluation of ICAP-supported programs while working side-by-side with its experts.


ACTG 5418 STOMP Study

  • current: Harlem
A randomized, placebo-controlled, double-blinded trial of the safety and efficacy of tecovirimat for the treatment of human monkeypox virus disease. https://actgnetwork.org/studies/a5418-study-of-tecovirimat-for-human-monkeypox-virus-stomp/; https://www.stomptpoxx.org/main ...

DMID 19-0004 (The MAGI Study)

  • current: Harlem
A Phase II randomized, observer-blind, placebo-controlled study to assess the efficacy of meningococcal Group B vaccine rMenB+OMV NZ (Bexsero) in preventing gonococcal infection Link(s): https://clinicaltrials.gov/ct2/show/NCT04350138 ...

HPTN 091: I AM Study

  • current: Harlem
HPTN 091 is a study assessing the feasibility, acceptability, preliminary impact of a multi-component strategy that provides HIV prevention services, gender-affirming hormone therapy, and Peer Health Navigation to improve pre-exposure prophylaxis (PrEP) uptake and adherence. Web Links: https://www.hptn.org/research/studies/hptn091 ...

HPTN 094: The INTEGRA Study

  • current: Bronx
A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and primary care Web Links: https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190 ...

HTPN 083: Give PrEP a Shot

  • current: Bronx, Harlem
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP and demonstrated the superiority of cabotegravir for HIV prevention in these populations.Closed to enrollment, in active study follow-up Web Links: https://clinicaltrials.gov/ct2/show/NCT02720094  https://www.hptn.org/research/studies/hptn083  ...

Making PrEP Smart

  • current: Bronx
The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month period. We will help you to download the app on your phone and provide you with HIV self-test kits and PrEP (if not already taking ...

The LEXICON Study 2.0

  • current: United States
The LGBTQ+ Experience in COVID-19 NYC Study. To assess the impact of COVID-19 on the lives and well-being of LGBTQ+ persons in NYC, the LEXICON study 2.0 will conduct a community-based online survey on the burden of COVID-19 disease, current use of COVID-19 preventative behaviors, COVID-19 vaccine willingness, access, and update among LGBTQ+ persons in ...

Clinical Trials

ICAP at Columbia University Clinical Trials Unit (ICAP CTU)

An innovative and comprehensive approach to HIV prevention and therapeutic research.

The ICAP CTU aims to support the design and implementation of research to address gaps in the global HIV response, including through clinical research sites in Harlem, Bronx, and Eswatini. Led by Wafaa El-Sadr, MD, MPH, MPA, and Jessica Justman, MD, this work is carried out through the ICAP at Columbia University Clinical Trials Unit (CTU). 

Learn more

ICAP in the United States

Active Years

2003 to present

Key Technical Areas
  • Clinical Research and Trials
  • COVID-19 Research
  • PrEP Research
  • Surveys
  • Sexually Transmitted Infections Research
Current Funders
  • The Rockefeller Foundation
  • The Samuels Foundation
  • The New York Community Trust



ICAP Founder and Global Director

Wafaa El-Sadr, MD, MPH, MPA

Dr. Wafaa El-Sadr is the founder and director of ICAP and an international expert in epidemiology and research on the prevention and management of HIV, tuberculosis, and other infectious diseases. She is also the director of Columbia World Projects. For over three decades, she has advocated for families and communities most impacted by HIV and championed a collaborative, multidisciplinary approach to confronting the global epidemic.

Based at Columbia University, she leads ICAP’s portfolio of projects in 30 countries and manages a global team of over 2,000 staff. Under her leadership, ICAP has become a global leader in HIV and health systems strengthening. She is also the director of the Mailman School’s Global Health Initiative (GHI), which mobilizes the University community to address critical challenges in global health.

Read more


The New York City Pandemic Response Institute (PRI)


PRI is a landmark initiative designed to help prepare NYC for future public health threats – from infectious diseases to climate-related health emergencies – by fortifying and diversifying the city’s public health infrastructure, improving health equity, and elevating NYC as a model of public health preparedness across the globe.

Learn more

Jobs in the United States

See the ICAP careers page to search all job listings.